Stock Update: CVS Caremark Corporation (NYSE:CVS) – CVS Health Research Institute Study Finds Newly Diagnosed Diabetes Patients Less Likely to Need Treatment Intensification When Started on a Generic Drug

[PR Newswire] – WOONSOCKET, R.I., Oct. 31, 2014 /PRNewswire/ — New research from CVS Health (CVS) finds starting a new diabetes patient on metformin, a generic oral diabetes medicine that helps control blood . . . → Read More: Stock Update: CVS Caremark Corporation (NYSE:CVS) – CVS Health Research Institute Study Finds Newly Diagnosed Diabetes Patients Less Likely to Need Treatment Intensification When Started on a Generic Drug Similar Articles: Stock Update: CVS Caremark Corporation (NYSE:CVS) – CVS Caremark Announces New Clinical Affiliation with MedStar Health Market Update (NYSE:LLY): New type 2 diabetes treatment Jardiance® (empagliflozin) tablets for adults now available in U.S. pharmacies Market Update (NYSE:CVS): CVS Caremark Announces New Clinical Affiliations with Four Major Regional Health Systems
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.